Trial reportJournal of cosmetic dermatology2025
Open-Label, Prospective Study of a Prebiotic Gel Cream on Its Efficacy of Mild to Moderate Acne Management and Effects on the Functional Skin Microbiome.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Open-Label, Prospective Study of a Prebiotic Gel Cream on Its Efficacy of Mild to Moderate Acne Management and Effects on the Functional Skin Microbiome.Journal of cosmetic dermatology · 2025Trial
- Microbiotherapy: an emerging adjunct for burn wound healing.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAcne vulgaris is a chronic inflammatory condition, which is estimated to affect greater than 85% of the population. Acne is a multifactorial condition, which can be influenced by diet, environment, and the microbiome.
aimsThe purpose of this clinical study is to assess the safety and effects of a prebiotic-containing gel cream on the skin microbiome of individuals with non-cystic acne-prone skin. PATIENTS/
methodsIn this 7-week clinical trial, 30 eligible participants were recruited and enrolled from the Sacramento region. The study consisted of three visits: (1) screening; (2) week 0, baseline; (3) week 6. All participants received a standard non-comedogenic cleanser and a prebiotic-containing gel cream. The primary endpoint in this study was alteration in C. acnes abundance in mild to moderate non-cystic, acne-prone skin. The secondary endpoint in this study was functional gene analysis for skin barrier and skin inflammation-related genes from whole genome sequencing of the skin microbiome.
resultsAcne lesions significantly reduced in non-inflammatory lesions, inflammatory lesions, and total lesions after treatment (-36.0%, -34.5%, and -35.9%, respectively). On the glabella, there was a 12.5 log2 fold increase in abundance of a healthy strain of C. acnes that is not associated with acne vulgaris. Furthermore, there was a wide range of functional bacterial genetic changes that may be associated with increased collagen and glutathione production. The gel cream was rated very well tolerated, and there were no adverse effects reported.
conclusionsThis prebiotic-containing gel cream can be an effective form of management for acne vulgaris by creating beneficial shifts in the skin microbiome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.